

N THE UNITED STATES PATENT AND TRADEMARK OFFICE.

In the Application of: Alitalo, et al.)	
)	I hereby certify that this paper is being
Serial No.: 09 534,376)	deposited with the United States Postal
)	Service as first class mail, postage
Filed: March 24, 2000)	prepaid, in an envelope addressed to:
)	Box Patent Application, Assistant
For:	VASCULAR ENDOTHELIAL)	Commissioner for Patents,
	GROWTH FACTOR C (VEGF-)	Washington, D.C. 20231, on this date:
	C) PROTEIN AND GENE,)	
	MUTANTS THEREOF, AND)	July 24, 2000
	USES THEREOF)	79 1 7 4 W
Group Art Unit: 1632)	David A. Gass
)	
Exam	iner: To Be Assigned)	

STATEMENT UNDER 37 C.F.R. §1.825

Box Patent Application Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

I hereby state that the content of the paper and computer readable copies of the substitute sequence listing, submitted herewith, are the same. All sequences in the substitute sequence listing submitted herewith are identical to those submitted in the original sequence listing. Differences between the two sequence listings pertain only to inserting proper description for "n" and "Xaa". The substitute sequence listing includes no new matter.

Respectfully submitted.

MARSHALL, O'TOOLE, GERSTEIN, MURRAY & BORUN

David A. Gass, Reg. No. 38,153

Attorneys for Applicants

6300 Sears Tower

233 South Wacker Drive

Chicago, Illinois 60606-6402

(312) 474-6300